Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction.
Infusion of the antitumor necrosis factor-alpha chimeric monoclonal antibody infliximab is highly effective in the treatment of refractory and fistulizing Crohn's disease (CD), but can be associated with the development of severe allergic reactions during retreatment, precluding further use of the medication. We present two CD patients (one adult and one child) with a history of anaphylactic/anaphylactoid reactions to retreatment with infliximab who subsequently underwent successful desensitization and therapeutic infusion using parenteral dose escalation in an intensive care unit setting.
Puchner
T C
TC
Department of Medicine, Digestive Disease Center, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, USA.
Kugathasan
S
S
Kelly
K J
KJ
Binion
D G
DG
D000328:Adult; D000707:Anaphylaxis / Q000209:etiology*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology*; D003888:Desensitization, Immunologic / Q000379:methods*; D005260:Female; D005765:Gastrointestinal Agents; D006801:Humans; D000069285:Infliximab; D007362:Intensive Care Units; D008297:Male
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab